Based on DESTINY-Breast04 results which showed
Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by
The approval by the
.
(C) 2022 M2 COMMUNICATIONS, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,296 GBX | -0.87% | +1.54% | +16.00% |
24/05 | Innate Pharma: five abstracts selected for ASCO | CF |
24/05 | Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial | MT |
Based on DESTINY-Breast04 results which showed
Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by
The approval by the
.
(C) 2022 M2 COMMUNICATIONS, source
1st Jan change | Capi. | |
---|---|---|
+16.00% | 243B | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B | |
+0.31% | 164B |